jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

ToRCH 8 Profile

Bacterial/ Viral

8 parameters

image

Report in 8Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Antibodies to TORCH pathogens.

₹1,599₹2,489

36% OFF

Parameters

  • List of Tests
    • Cytomegalo Virus (CMV) - IgG
    • Cytomegalo Virus (CMV) - IgM
    • Herpes Simplex Virus (HSV I & II) - IgG
    • Herpes Simplex Virus (HSV I & II) - IgM
    • Rubella - IgG
    • Rubella - IgM
    • Toxoplasma Gondii - IgG
    • Toxoplasma Gondii - IgM

ToRCH 8 Profile - Comprehensive Medical Test Guide

  • Why is it done?
    • The ToRCH 8 Profile is a comprehensive serological screening panel that detects antibodies to four major congenital and perinatal pathogens: Toxoplasma gondii, Rubella virus, Cytomegalovirus (CMV), and Herpes Simplex Virus (HSV I & II)
    • Primary indication: Screening pregnant women or those planning pregnancy to assess immunity and prior exposure to infections that can cause serious fetal complications, birth defects, or neonatal disease
    • Evaluates both IgG antibodies (indicating past infection, immunity, or chronic infection) and IgM antibodies (indicating acute or recent infection) for each pathogen
    • CMV-IgG and CMV-IgM: Screen for cytomegalovirus, a common herpesvirus that can cause congenital infection, hearing loss, developmental delays, and microcephaly in fetuses
    • HSV I & II-IgG and HSV I & II-IgM: Detect herpes simplex virus exposure; primary HSV infection during pregnancy increases risk of neonatal herpes, which can cause serious complications including encephalitis and disseminated disease
    • Rubella-IgG and Rubella-IgM: Assess immunity and detect rubella virus; maternal rubella infection during pregnancy can cause congenital rubella syndrome with cardiac defects, eye abnormalities, and intellectual disability
    • Toxoplasma Gondii-IgG and Toxoplasma Gondii-IgM: Screen for parasitic infection acquired through cat feces or undercooked meat; congenital toxoplasmosis can cause chorioretinitis, hydrocephalus, and intrauterine growth restriction
    • Recommended during preconception planning, first trimester of pregnancy, and in non-immune pregnant women for baseline risk stratification
    • Also indicated in immunocompromised patients, neonates with suspected congenital infection, or patients with signs and symptoms compatible with these infections
    • The eight-component panel provides a comprehensive risk assessment by testing both acute (IgM) and chronic/immune (IgG) markers simultaneously, allowing for complete clinical interpretation
  • Normal Range
    • Cytomegalo Virus (CMV) - IgG: Negative or <0.8 IU/mL (or as per laboratory reference); indicates no prior CMV infection or immunity from vaccination (if available)
    • Cytomegalo Virus (CMV) - IgM: Negative or <0.8 IU/mL; indicates no acute or recent CMV infection
    • Herpes Simplex Virus (HSV I & II) - IgG: Negative or <0.8 IU/mL; indicates no prior HSV exposure or immunity
    • Herpes Simplex Virus (HSV I & II) - IgM: Negative or <0.8 IU/mL; indicates no acute or primary HSV infection
    • Rubella - IgG: Positive or ≥10-15 IU/mL (varies by laboratory); indicates immunity from vaccination or prior infection; protective level is generally considered ≥10-15 IU/mL
    • Rubella - IgM: Negative or <0.8 IU/mL; indicates no acute or recent rubella infection
    • Toxoplasma Gondii - IgG: Negative or <4 IU/mL (reference range varies); indicates no prior toxoplasma infection or immunity
    • Toxoplasma Gondii - IgM: Negative or <0.8 IU/mL; indicates no acute or recent toxoplasma infection
    • Interpretation categories: Negative/Non-reactive (no detected antibodies), Positive/Reactive (antibodies detected), Equivocal/Borderline (results near cutoff requiring repeat testing or additional confirmation)
    • Unit of measurement: IU/mL (International Units per milliliter) or antibody index ratio; specific reference ranges vary by laboratory methodology (ELISA, chemiluminescence, etc.)
    • Negative IgG with negative IgM: No evidence of current or recent infection; for rubella, negative IgG indicates non-immunity and vaccination is recommended
    • Positive IgG with negative IgM: Chronic infection, past infection, or established immunity; no acute infection
    • Positive IgM with positive or negative IgG: Acute or recent infection; requires further investigation and clinical correlation
  • Interpretation
    • CMV-IgG Positive: Indicates prior CMV infection or exposure; patient has developed immunity but virus may reactivate; particularly concerning if acute IgM is also positive in pregnancy
    • CMV-IgM Positive: Suggests acute or recently acquired CMV infection; in pregnant women, indicates risk of vertical transmission and potential congenital CMV with sequelae including sensorineural hearing loss, microcephaly, and neurological complications
    • CMV-IgG Negative: No prior CMV infection; patient is susceptible to primary CMV infection; pregnant women with negative IgG require counseling on transmission prevention and high-risk behavior avoidance
    • HSV I & II-IgG Positive: Indicates prior exposure to HSV type I and/or II; confers partial protection against severe disease but risk of reactivation exists; in pregnancy, primary infection carries higher risk than recurrent infection
    • HSV I & II-IgM Positive: Indicates acute or primary HSV infection; in pregnant women, particularly concerning if occurring near delivery date; substantially increases risk of neonatal herpes with potential for severe complications including CNS disease and disseminated infection
    • HSV I & II-IgG Negative: No documented prior HSV exposure; patient is susceptible to primary infection which carries higher risk of severe disease in immunocompromised individuals and pregnant women
    • Rubella-IgG Positive (≥10-15 IU/mL): Indicates immunity from vaccination or prior infection; protects against rubella infection; considered immune for practical purposes
    • Rubella-IgG Borderline (5-9 IU/mL): Equivocal immunity status; repeat testing recommended; vaccination may be considered if originally vaccinated or immunity is questionable
    • Rubella-IgG Negative (<5 IU/mL): No immunity; patient susceptible to rubella; vaccination strongly recommended prior to pregnancy; cannot vaccinate during pregnancy
    • Rubella-IgM Positive: Indicates acute or recent rubella infection; in pregnancy, carries significant risk of congenital rubella syndrome especially if first trimester infection, causing cardiac defects, ocular abnormalities, deafness, and growth restriction
    • Toxoplasma Gondii-IgG Positive: Indicates prior or chronic toxoplasma infection; patient is generally immune to reinfection but risk of reactivation exists in severely immunocompromised patients
    • Toxoplasma Gondii-IgM Positive: Indicates acute or recent toxoplasma infection; in pregnancy, indicates risk of congenital transmission with potential for serious fetal complications including chorioretinitis, hydrocephalus, intracranial calcifications, and growth restriction
    • Toxoplasma Gondii-IgG Negative: No prior toxoplasma infection; patient susceptible to acute infection; pregnant women require counseling on prevention (proper food handling, cat feces avoidance)
    • Factors affecting results: Cross-reactivity between HSV I and II may not distinguish type-specific infection; false positives possible with autoimmune conditions or recent vaccinations; false negatives during acute window period before antibody development
    • IgM testing limitations: May not detect infections in early acute phase; can persist for months requiring clinical correlation; equivocal results are common and warrant repeat testing or additional confirmatory methods
    • Positive IgM requires clinical correlation with symptoms; timing of infection; and consideration of repeat testing to assess IgM trend (rising suggests acute infection)
    • Laboratory methodology affects results: Different assays (ELISA, chemiluminescence, fluorescent antibody) may have varying sensitivity and specificity; reference ranges should be interpreted per individual laboratory guidelines
  • Associated Organs
    • CMV-IgG and IgM: Central nervous system (CNS) involvement with potential microcephaly, ventriculomegaly, and developmental delay; hearing system with sensorineural hearing loss; eyes with chorioretinitis and vision impairment; hepatic system with hepatomegaly and liver dysfunction
    • CMV congenital infection complications: Thrombocytopenia, hemolytic anemia, intrauterine growth restriction, prematurity, and long-term neurodevelopmental sequelae affecting cognitive and motor functions
    • HSV I & II-IgG and IgM: Central nervous system with HSV encephalitis, meningitis, and disseminated CNS disease; skin and mucous membranes with vesicular lesions; neonatal disseminated disease affecting multiple organ systems including liver, lungs, and brain
    • HSV maternal infection during pregnancy: Risk of ascending intrauterine infection in early pregnancy; higher risk of neonatal herpes when primary infection occurs near term; potential for disseminated neonatal disease with mortality reaching 30% without treatment
    • Rubella-IgG and IgM: Organ systems affected in congenital rubella syndrome include cardiac (patent ductus arteriosus, pulmonary stenosis, myocarditis), ocular (cataracts, glaucoma, retinopathy), auditory (sensorineural hearing loss), and CNS (microcephaly, intellectual disability)
    • Rubella congenital infection: Multiple organ involvement with growth restriction, hepatosplenomegaly, thrombocytopenia, bone abnormalities, and chronic infection persisting into childhood with ongoing viral shedding
    • Toxoplasma Gondii-IgG and IgM: Central nervous system with intracerebral calcifications, hydrocephalus, and seizure disorders; ocular system with chorioretinitis leading to vision loss or blindness; multisystem involvement with hepatomegaly, splenomegaly, and myocarditis
    • Congenital toxoplasmosis: Classic triad of chorioretinitis, intracranial calcifications, and hydrocephalus; intrauterine growth restriction; intellectual disability; potential for late manifestations of ocular disease and seizure disorders
    • Immune system: All tested pathogens affect immune function; IgG indicates immune response and relative protection; IgM indicates acute immune response; immunocompromised patients at higher risk for severe manifestations and reactivation disease
    • Reproductive system: Primary concern is transplacental transmission and fetal consequences; maternal viremia increases risk of vertical transmission; gestational timing affects severity of fetal infection and clinical outcomes
    • First trimester infections generally carry higher risk of severe congenital manifestations compared to third trimester infections; risk of vertical transmission increases with gestational age
  • Follow-up Tests
    • CMV: If IgM positive, recommend CMV viral load (PCR) testing on blood to quantify viral replication and assess active infection; CMV quantitative PCR on amniotic fluid (after 18-20 weeks gestation) to assess fetal infection; high-resolution ultrasound for fetal anomalies
    • CMV: Neonatal testing should include CMV culture from urine and saliva; CMV PCR; hearing assessment with auditory brainstem response (ABR) testing; neuroimaging with ultrasound or MRI if congenital infection suspected
    • CMV: Monitoring frequency for IgM-positive pregnant women includes repeat serology at 2-4 weeks to assess trends; serial ultrasounds every 4 weeks to monitor for fetal abnormalities; close obstetrician communication for delivery planning
    • HSV: If IgM positive, recommend HSV PCR from genital lesions if present; HSV viral culture; repeat serology at 1-2 weeks to differentiate primary infection (rising IgG) from recurrent infection; neonatal assessment if delivery approaching
    • HSV: Neonatal follow-up includes HSV PCR from blood, CSF, and mucous membranes; viral culture from skin vesicles; lumbar puncture if neonatal herpes suspected; imaging with head ultrasound or MRI if CNS involvement concerns
    • HSV: Pregnant women with primary HSV IgM positive near delivery typically require cesarean section delivery; close monitoring in final trimester; assessment for active lesions at delivery; neonatal prophylaxis if vaginal delivery occurs
    • Rubella: If IgM positive, repeat serology at 1-2 weeks to confirm acute infection; ultrasound assessment for fetal anomalies; consider amniocentesis after 18-20 weeks for rubella PCR if first trimester infection
    • Rubella: Neonatal rubella assessment includes serology (IgG and IgM) from infant; rubella culture from nasopharynx, urine, or CSF; audiometry for hearing assessment; ophthalmologic evaluation for eye abnormalities
    • Rubella: Non-immune pregnant women (IgG negative) require MMR vaccination post-delivery; vaccination counseling emphasizing immunity importance; serologic confirmation of immunity 4-8 weeks after vaccination
    • Toxoplasma: If IgM positive, recommend toxoplasma PCR (when available) and specific avidity testing to assess timing of infection; ultrasound for fetal abnormalities; amniocentesis after 18-20 weeks for fetal toxoplasma PCR
    • Toxoplasma: IgG-positive pregnant women benefit from serial surveillance ultrasounds and potentially prophylactic treatment (spiramycin) to reduce transmission risk; IgG-negative women require dietary and behavioral counseling
    • Toxoplasma: Neonatal follow-up includes infant serology (IgG and IgM) repeated at 4-6 weeks; ophthalmologic examination for chorioretinitis; head ultrasound or MRI for intracranial calcifications; developmental assessment
    • General follow-up: Equivocal IgM results warrant repeat testing in 1-2 weeks; borderline IgG results (rubella) may need repeat testing or additional confirmation; positive results in immunocompromised patients require additional investigation and consideration of reactivation disease
    • Complementary testing: Complete blood count (CBC) for anemia, thrombocytopenia; liver function tests for hepatic involvement; ultrasound imaging (obstetric or abdominal depending on clinical context)
    • Monitoring in pregnancy: Baseline testing at first prenatal visit; repeat serology in second and third trimesters for women with negative results to detect seroconversion; more frequent monitoring for positive IgM results
    • Type-specific HSV testing: If HSV I & II IgG/IgM positive, may benefit from type-specific serology (HSV-1 vs HSV-2 specific antibodies) to distinguish infection types and guide management decisions
  • Fasting Required?
    • Fasting Required: No - The ToRCH 8 Profile serology testing does not require fasting; blood can be drawn at any time of day regardless of meal intake
    • Specimen collection: Venous blood draw (serum separator tube); no special collection requirements; routine collection procedures apply
    • Medications: No medications require discontinuation prior to testing; existing medications do not affect antibody detection and should be continued as prescribed
    • Dietary restrictions: No dietary restrictions required; patient may eat and drink normally before testing; no special preparation needed
    • Vaccine considerations: If patient recently received live vaccines (MMR, varicella), serology should ideally be performed at least 4 weeks after vaccination to avoid potential interference; however, antibodies from vaccines do not typically interfere with serology
    • Timing for pregnancy testing: Ideally performed in preconception period or first trimester; most critical in first 8-12 weeks of pregnancy; can be performed at any time but results guide management throughout pregnancy
    • Patient preparation: No specific fasting period required; patient should be calm and relaxed during blood draw; inform healthcare provider of any bleeding disorders or anticoagulation therapy
    • Specimen handling: Blood should be refrigerated if there will be a delay in testing; results typically available within 24-48 hours; order testing through healthcare provider to ensure appropriate specimen handling and turnaround time
    • Special circumstances: Immunocompromised patients may have delayed or blunted antibody responses affecting result interpretation; repeat testing may be needed if results are equivocal; patient medical history should be communicated to laboratory

How our test process works!

customers
customers